Skip to main content

Table 2 Incidence of treatment-related grade ≥ 3 adverse events by patient characteristics in patients with PTCL a

From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

  No. Infection Thrombocytopenia Neutropenia Anemia Asthenic conditions Nausea and vomiting
PTCL subtypes
  PTCL NOS 69 4 20 17 4 7 4
  AITL 27 4 30 22 7 4 0
  ALK-1–negative ALCL 21 5 24 14 0 5 5
  Other 14 21 31 36 14 0 7
Age
  < 65 years 86 6 23 22 6 4 6
  ≥ 65 years 45 7 22 16 4 9 0
International Prognostic Index score
  0-1 31 3 19 13 10 0 7
  ≥ 2 100 7 24 22 4 7 3
Prior systemic therapies
  < 3 83 6 15b 21 8 5 5
  ≥ 3 48 6 38b 19 0 6 2
Prior stem cell transplant
  Yes 21 0 33 10 5 5 0
  No 110 7 21 22 6 6 5
Prior monoclonal antibody therapyc
  Yes 20 20d 35 50e 5 5 0
  No 111 4d 21 14e 5 5 5
Bone marrow involvement
  Yes 37 8 30 24 5 5 0
  No 94 5 20 18 5 5 5
  1. AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; PTCL NOS, peripheral T-cell lymphoma not otherwise specified.
  2. aAll comparisons except those noted below were not significant (P > .05).
  3. bPrimarily rituximab or alemtuzumab.
  4. c P = .005.
  5. d P = .019.
  6. e P < .001.